Paper Details

  1. Home
  2. Paper Details

Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.

Author: FengPeimin, LeiHonglin, LeiRong, LiYilin, XieFengjiao, XiongQin, YaoChengjiao

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This network meta-analysis systematically compares the drug-related side effects of different pharmacological agents used for treating liver fibrosis in NAFLD. The analysis found that lanifibranor, liraglutide, semaglutide, cenicriviroc, MSDC-0602K, and obeticholic acid have the highest risk of side effects in patients with NAFLD.
Paper Details　
Original Abstract of the Article :
Several studies have found that antifibrosis treatment for nonalcoholic fatty liver disease (NAFLD) can cause a variety of side effects. No network meta-analysis (NMA) analyzes the adverse events of antifibrotic drugs for NAFLD. This NMA aimed to systematically compare the drug-related side effects ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/36468565

データ提供：米国国立医学図書館（NLM）

Side Effects of Pharmacologic Therapies for Liver Fibrosis in NAFLD: A Systematic Review and Network Meta-Analysis

This research explores the side effect profiles of various medications used to treat liver fibrosis in nonalcoholic fatty liver disease (NAFLD). The authors conducted a comprehensive systematic review and network meta-analysis, pooling data from multiple randomized controlled trials (RCTs) to compare the risk of different side effects associated with various pharmacological agents. They found that different medications had varying risks of different side effects. For example, lanifibranor was associated with a higher risk of diarrhea, while liraglutide was associated with a higher risk of constipation. Semaglutide, cenicriviroc, MSDC-0602K, and obeticholic acid were also associated with specific side effects, highlighting the importance of carefully considering the potential risks and benefits of each treatment option.

Navigating the Side Effect Landscape of NAFLD Medications

The research shows that each medication for NAFLD comes with its own unique set of potential side effects. Just like the different types of sand dunes in a desert, each medication has its own distinct characteristics. This knowledge is crucial for clinicians to make informed decisions about treatment strategies for individual patients, weighing the potential benefits against the potential risks.

Making Informed Decisions about NAFLD Treatment

Understanding the potential side effects of different NAFLD medications is essential for patients and their healthcare providers to make informed decisions. It's crucial to discuss any concerns about potential side effects with your physician and to monitor your body for any unusual symptoms. Working together, patients and their doctors can create a personalized treatment plan that minimizes risks and maximizes benefits.

Dr.Camel's Conclusion

This research reminds us that even promising new medications can have side effects. Understanding these side effects is crucial for making informed decisions about NAFLD treatment. The study provides a valuable guide for clinicians and researchers to navigate the diverse landscape of NAFLD medications, ensuring that patients receive the best possible care.

Date :
  1. Date Completed 2022-12-06
  2. Date Revised 2023-02-03
Further Info :

Pubmed ID

36468565

DOI: Digital Object Identifier

00042737-202301000-00001

Related Literature

Article Analysis
・Side Effects of obeticholic acid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.